IN THE NEWS
-
INTEGRAGEN RENEWS PARTNERSHIP AGREEMENT WITH INSTITUT PASTEUR FOR HIGH THROUGHPUT SEQUENCING IN MICROBIOLOGY
IntegraGen today announced the renewal, until December 2021, of its partnership agreement with the Institut Pasteur relating to high throughput sequencing operations for microbiology activities carried out... Read More
-
INTEGRAGEN PRESENTS RESULTS OF A STUDY EXTENDING THE IMPACT OF MIR-31 EXPRESSION MEASUREMENT TO STAGE III COLON CANCER PATIENTS AT ESMO 2018
Analysis of samples from the PETACC 8 phase III clinical trial shows that miR-31 expression levels identify sub-populations of cancer patients... Read More
-
INTEGRAGEN NOMINATED FOR THE GALIEN MEDSTARTUP AWARD 2018
IntegraGen has been nominated for the Prix Galien MedStartup 2018, a joint initiative between the Galien Foundation and Business France to encourage and reward international partnerships between... Read More
LATEST NEWS
-
INTEGRAGEN: A STRUCTURING DOUBLE AGREEMENT WITH TWIST BIOSCIENCE - INTERVIEW WITH BERNARD COURTIEU IN BIOTECH FINANCE
Bernard Courtieu answers questions from Pierre-Louis Germain, "Biotech Finance" specialist journalist, about the... Read More
-
PRESENTATION OF NEW RESULTS ON THE MIR-31-3P BIOMARKER IN AN ORAL PRESENTATION AT THE ESMO 2016 CONGRESS IN COPENHAGEN
The results of new analyses carried out on the FIRE-3 trial on the predictive role of the marker... Read More
-
RESULTS OF MIR-31-3P EXPRESSION ANALYSIS IN THE FIRE-3 STUDY TO BE PRESENTED AT THE ASCO 2016 CONGRESS
he results of mir31-3p expression analysis in the FIRE-3 colon cancer study... Read More
-
INTEGRAGEN CONVENES SCIENTIFIC COMMITTEE TO REVIEW LATEST MIR-31-3P CLINICAL DATA
IntegraGen convened its Oncology Scientific Committee at the 2016 Gastro Intestinal Symposium in... Read More
